Acarbose effect in metabolic syndrome
Phase 3
- Conditions
- Obesity.Overweight and obesity
- Registration Number
- IRCT20130924014752N5
- Lead Sponsor
- Endocine Research Center of Isfahan University of Medical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 80
Inclusion Criteria
BMI=30 or more than 30
Affected by metabolic syndrome
Female
Age between 20_50 years
Exclusion Criteria
Chronic disease beside metabolic syndrome
Non cooperative
Consuming anti Lipid drugs
Consuming Metformin in past year
Weight loss or diet in past year
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Body weight. Timepoint: At the first visit and each two weeks after three month of consumption of total dose of drug or dose of patient tolerance. Method of measurement: Body weight scales.;Height. Timepoint: At first visit and last visit. Method of measurement: Height gauge.;Waist. Timepoint: At first visit and last visit. Method of measurement: Strip meter.;Fasting blood suger. Timepoint: At first visit and end of study. Method of measurement: Enzymatic lab study.;Insulin level of serum. Timepoint: At first visit and end of study. Method of measurement: ELISA method.;Epicardial fat thickness. Timepoint: At first visit and end of study. Method of measurement: Echocardiography.;Body Mass Index (BMI). Timepoint: At first visit and end of study. Method of measurement: BMI = kg/m2 person's weight in kilograms and m2 is their height in metres squared.
- Secondary Outcome Measures
Name Time Method Flatulence. Timepoint: Each two weeks. Method of measurement: Questioner.